30 March 2022 : Clinical Research
Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse
Liyang Zhou1ABCDEF, Qin He1CEF, Xitao Liu2DEF, Xiaoan Yang3BC, Xueting Ou3EF, Bing Situ2DF, Yueping Li4DE, Xingfei Pan1DEFG*, Qihuan Xu3AEDOI: 10.12659/MSM.934785
Med Sci Monit 2022; 28:e934785
Table 4 Univariate and multivariate Cox analysis of factors associated with sustained clinical suppression after pegylated interferon-alpha regimen was completed.
| Factors | Univariate | Multivariate | Multivariate after adjustment | |||
|---|---|---|---|---|---|---|
| RR (95% CI) | P | RR (95% CI) | P | RR (95% CI) | P | |
| Antiviral history | 0.279 (0.098~0.794) | 0.017 | 0.147 (0.026~0.824) | 0.029 | 0.164 (0.048~0.558) | 0.004 |
| ALT at 0 week | 1.002 (1.000~1.004) | 0.041 | 1.002 (0.999~1.005) | 0.114 | – | – |
| AST at 24 weeks | 0.982 (0.966~0.999) | 0.036 | 0.981 (0.953~1.009) | 0.175 | – | – |
| HBsAg at 36 weeks | 1.000 (1.000~1.001) | 0.000 | 1.000 (0.999~1.000) | 0.314 | – | – |
| HBsAg at 48 weeks | 1.000 (1.000~1.000) | 0.000 | 1.000 (1.000~1.001) | 0.032 | 2.697 (1.051~6.920) | 0.039 |
| ALT at 24 weeks of follow-up | 9.322 (4.042~21.499) | 0.000 | 4.131 (1.079~15.810) | 0.038 | 5.467 (1.705~17.524) | 0.004 |
| Peg-IFNα – pegylated interferon alfa; HBsAg – hepatitis B surface antigen; ALT – alanine aminotransferase; AST – aspartate aminotransferase. | ||||||